WO2007052541A1 - Prodrug of donepezil hydrochloride - Google Patents
Prodrug of donepezil hydrochloride Download PDFInfo
- Publication number
- WO2007052541A1 WO2007052541A1 PCT/JP2006/321443 JP2006321443W WO2007052541A1 WO 2007052541 A1 WO2007052541 A1 WO 2007052541A1 JP 2006321443 W JP2006321443 W JP 2006321443W WO 2007052541 A1 WO2007052541 A1 WO 2007052541A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- optionally substituted
- substituents selected
- substituent
- salt
- Prior art date
Links
- FXFBNVVVTBOTHW-UHFFFAOYSA-N CC(OC(c1c2)=C(CC3CCN(CC4C=CC=CC4)CC3)Cc1cc(OC)c2OC)=O Chemical compound CC(OC(c1c2)=C(CC3CCN(CC4C=CC=CC4)CC3)Cc1cc(OC)c2OC)=O FXFBNVVVTBOTHW-UHFFFAOYSA-N 0.000 description 1
- 0 COc(c(OC)c1)cc2c1C(*)=C(CC1CCN(Cc3ccccc3)CC1)C2 Chemical compound COc(c(OC)c1)cc2c1C(*)=C(CC1CCN(Cc3ccccc3)CC1)C2 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
Definitions
- the present invention relates to a novel prodrug of donepezil hydrochloride, which is a therapeutic agent for Alzheimer type dementia, a process for production thereof and a pharmaceutical composition containing them.
- senile dementia represented by Alzheimer type dementia has become a serious problem with a growth of the aged population, and the development of an excellent therapeutic agent for senile dementia is eagerly desired.
- ⁇ It has been reported that in case of Alzheimer type dementia, the amounts of neurotransmitters such as acetylcholine, norepinephrine and serotonin are decreased with the accumulation of ⁇ - amyloids.
- the cholinesterase inhibitor that controlled the decomposition of the acetylcholine was developed by focusing attention on the close relation to the decrease in the cognitive function including the memory to the degeneration of cholinergic neuron.
- the cholinesterase inhibitors used as a therapeutic agent for Alzheimer type dementia includes donepezil hydrochloride, rivastigmine and galantamine, etc.
- donepezil hydrochloride is an excellent therapeutic agent characterized by a few peripheral side effect based on the high selectivity of acetylcholinesterase to butyrylcholinesterase and by the long half-life in blood etc. (see Japanese Patent No. 2578475, Japanese Patent No. 2777159 and J of Med Chem (1995) 38, 4821) .
- donepezil hydrochloride is effective against a mild or medium case of Alzheimer type dementia.
- the effect of donepezil hydrochloride is the suppression of the progress of dementia symptoms in a mild or medium case of Alzheimer type dementia.
- an additional application for launching donepezil hydrochloride with new efficacy and effect on a serious case of Alzheimer type dementia has been made.
- Donepezil hydrochloride is a very excellent therapeutic agent for Alzheimer type dementia from the viewpoint of efficacy, absorption, distribution, toxicity and the like and is most commonly used all over the world.
- Donepezil causes a rapid increase of its blood level after administration because of its satisfactory absorption and distribution, to exhibit its efficacy.
- the side effects of donepezil hydrochloride such as vomit, diarrhea and nightmare are observed which are considered to be due to the rapid increase of the blood level of donepezil caused soon after administration.
- the remission and reduction of the side effects e.g. vomit, diarrhea and nightmare caused in some cases are a problem to be solved for the present invention.
- the present inventors earnestly made efforts in order to solve the above problem, and consequently could prevent the rapid increase of the blood level of donepezil by converting donepezil to a prodrug to retard the release of the pharmaceutical activity itself into blood.
- This prevention permits remission and reduction of the above-mentioned side effects (e.g. vomit, diarrhea and nightmare) observed in some cases, whereby the present invention has been accomplished.
- the present invention relates to a compound -represented by the formula (I):
- R is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group ⁇ , a carbamoyl group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxycarbonyl group optionally substituted by one to three substituents selected from the substituent group ⁇ , a C2-6 alkanoyl group optionally substituted by one to three substituents selected from the substituent group ⁇ , or a C6-14 arylcarbonyl group optionally substituted by one to three substituents selected from the substituent group ⁇ ; and n is an integer of 0 or 1, or a pharmaceutically acceptable salt thereof; said substituent group ⁇ consisting of a Cl-6 alkoxy group, a C2-6 alkenyl group, a Cl-6 alkyl group, a Cl-6 alkylthio group, a C2-6 alkynyl group, a C6-14 aryl group, a cyano group, a
- the present invention also relates to a process for producing a compound represented by the formula (I ) :
- R 1 is an amino group optionally substituted by one or two Cl- ⁇ alkyl groups, a C6-14 aryloxy group optionally substituted by , one to three substituents selected from the substituent group ⁇ as defined above, a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent ⁇ as defined above, or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group ⁇ as defined above; and X is a leaving group, or reacting a compound represented by the formula (III) :
- R 2 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group ⁇ as defined above, thereby obtaining a compound represented by the formula (II) :
- R is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group ⁇ as defined above, a carbamoyl group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxycarbonyl group optionally substituted by one to three substituents selected from the substituent group ⁇ as defined above, a C2-6 alkanoyl group optionally substituted by one to three substituents selected from the substituent group ⁇ as defined above, or a C6-14 arylcarbonyl group optionally substituted by one to three substituents selected from the substituent group ⁇ as defined above, or a salt thereof, and if necessary, subjecting the compound of the formula (II) or a salt thereof to salt forming reaction and/or oxidation reaction.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined above, as an active ingredient.
- the compound of the formula (I) of the present invention is expected to be effective in the treatment, prevention, remission, amelioration and the like of, for example, a cerebral accident (e.g. cerebral hemorrhage or cerebral infarction) , cerebral arteriosclerosis, or a head injury; and aprosexia,' lalopathy, hypobulia, emotional disturbance, memory- disturbance, hallucinatory-paranoid syndrome, behavioral abnormality which are associated with, for example, encephalitis or cerebral palsy.
- a cerebral accident e.g. cerebral hemorrhage or cerebral infarction
- cerebral arteriosclerosis e.g. cerebral arteriosclerosis
- a head injury e.g. cerebral arteriosclerosis
- aprosexia,' lalopathy, hypobulia e.g. cerebral arteriosclerosis, or a head injury
- aprosexia,' lalopathy, hypobulia e.g. cerebral arteriosclerosis, or a head injury
- the remission and reduction of, the side effects (e.g. vomit, diarrhea and nightmare) observed in some cases after the administration of donepezil hydrochloride are the expected advantages of the present invention.
- halogen atom means a fluorine atom, a chlorine atom, a bromine atom, an iodine atom or the like, preferably a chlorine atom or a bromine atom.
- C3-8 cycloalkyl group means a cyclic alkyl group of 3 to 8 carbon atoms. Preferable examples of this group are cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc.
- Cl-6 alkyl group means an alkyl group of 1 to 6 carbon atoms.
- Preferable examples ' of this " group are linear or branched alkyl groups such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group, n- pentyl group, isopentyl group, neopentyl group, n-hexyl group, 1-methylpropyl group, 1, 2-dimethylpropyl group, 1-ethylpropyl group, l-methyl-2-ethylpropyl group, 1- ethyl-2-methylpropyl group, 1, 1, 2-trimethylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1- dimethylbutyl group, 2, 2-dimethylbutyl group, 2- ethylbutyl group, 1, 3-dimethylbutyl group, 2- methylpentyl group, 3-methylpentyl group, etc.
- alkyl groups such as
- C2-6 alkenyl group means an alkenyl group of 2 to 6 carbon atoms.
- Preferable examples of this group are linear or branched alkenyl groups such as vinyl group, allyl group, 1-propenyl group, isopropenyl group, 1-buten-l-yl group, 1-buten- 2-yl group, l-buten-3-yl, 2-buten-l-yl group, 2-buten- 2-yl group, etc.
- C2-6 alkynyl group means an alkynyl group of 2 to 6 carbon atoms. Preferable examples of this group ' are linear or branched alkynyl groups such as ethynyl group, 1-propynyl group, 2- propynyl group, butynyl group, pentynyl group, hexynyl •group, etc.
- Cl-6 alkoxy group means a group formed by the replacement of a hydrogen atom of an ' alkyl group of 1 to 6 carbon atoms by an oxygen atom.
- This group includes, for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, t-butoxy group, n-pentyloxy group, isopentyloxy group, sec-' pentyloxy group, t-pentyloxy group, n-hexyloxy group, isohexyloxy group, 1, 2-dimethylpropoxy group, 2- ethylpropoxy group, l-methyl-2-ethylpropoxy group, 1- ethyl-2-methylpropoxy group,, 1, 1, 2-trimethylpropoxy group, 1, 1-dimethylbutoxy group, 2, 2-dimethylbutoxy group, 2-ethylbutoxy group, 1, 3-dimethylbutoxy group, 2-methylpentyloxy group, 3-methylpentyloxy group and hexyloxy group.
- C3-8 -cycloalkoxy group means a group formed by the replacement of a hydrogen atom of a cyclic alkyl group of 3 to 8 carbon atoms by an oxygen atom.
- This group includes, for example, cyclopropoxy group, cyclobutoxy group, cyclopentyloxy group, cyclohexyloxy group, cycloheptyloxy group and cyclooctyloxy group.
- Cl-6 alkylthio group means a group formed by the replacement of a hydrogen atom of an alkyl group of 1 to 6 ea-rbon atoms by a sulfur atom.
- This group includes, for ⁇ -example, methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, • isobutyPthio group, t- butylthio group, n-pentylthio group, isopentylthio group, neopentylthio group, n-hexylthio group and 1- methylpropylthio group.
- C3-8 cycloalkylthio group means a group formed by the replacement of a hydrogen atom of a cyclic alkyl group of 3 to 8 carbon atoms by a sulfur atom.
- This group includes, for example, cyclopropylthio group, cyclobutylthio group, cyclopentylthio group, cyclohexylthio group, cycloheptylthio group and cyclooctylthio group.
- the "C6-14 aryl group” includes, for example, phenyl group, naphthyl group and anthryl group. Of these, phenyl group is preferable.
- C6-14 aryloxycarbonyl group means a group formed by bonding of a carbonyl group to the phenolic hydroxyl group of an aryloxy group of 6 to 14 carbon atoms. Preferable examples of this group are phenoxycarbonyl group, naphthyloxycarbonyl group, anthryloxycarbonyl group, etc. Phenoxycarbonyl group is more preferable.
- C6-14 arylcarbonyl group means a group formed by bonding of a carbonyl group to an aromatic ring of 6 to 14 carbon atoms. Preferable examples of this group are benzoyl group, naphthoyl group, etc. Benzoyl group is more preferable.
- C2-6 alkanoyl group means an alkanoyl group of 2 to 6 carbon atoms. Preferable examples of this group are acetyl group, propanoyl group, butanoyl group, pentanoyl group and hexanoyl group.
- substituted group ⁇ means the group consisting of a Cl-6 alkoxy group, a C2-6 alkenyl group, a Cl- ⁇ alkyl group, a Cl-6 alkylthio group, a C2-6 alkynyl group, a C6-14 aryl group, a cyano group, a C3-8 cycloalkoxy group, a C3-8 cycloalkyl group, ; a C3-8 cycloalkylthio group, a halogen atom and a nitro group.
- pharmaceutically acceptable salt means a salt of the compound (I) which can be used as an active agent of a pharmaceutical composition.
- a salt may include a mineral acid salt such as hydrochloride, hydrobromide, sulfate and nitrate; an inorganic acid salt such as perchlorate, phosphate, carbonate and bicarbonate; an organic carboxylate such as acetate, oxalate, maleate, tartarate, fumarate and citrate; an organic sulfonate such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate and camphorsulfonate; an amino acid salt such as aspartate and glutamate; a quaternary amine salt; an alkali metal salt such as sodium salt and potassium salt; and an alkali-earth metal salt such as magnesium salt and calcium salt.
- salt'.' means the same meanings as those of the term “pharmaceutically acceptable salt” as mentioned above.
- the compound (I) or a salt thereof is synthesized by the use of a compound (III) or a salt thereof, which is donepezil or donepezil salt, as a starting material as shown below.
- R 1 is an amino group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxy group optionally substituted by one to three substituents selected from the substituent group ⁇ , a Cl- ⁇ alkyl group optionally substituted by one to three substituents selected from the substituent group ⁇ , or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group ⁇ ; and X is a leaving group.
- R 1 when R 1 is an amino group optionally substituted by one or two Cl- ⁇ alkyl groups, the reaction is carried out in pyridine solvent in a sealed tube at a temperature of 0 to 100°C, preferably 90 0 C.
- R 1 is an C ⁇ -14 aryloxy group optionally substituted by one to three substituents selected from the substituent group ⁇ , or when R 1 is an Cl- ⁇ alkyl group optionally substituted by a substituent (s) selected from the substituent group ⁇ , or a C6-14 aryl group optionally substituted by a substituent (s) selected from the substituent gxoup ⁇
- the reaction is carried out at -60°C to room temperature in an inert solvent such as tetrahydrofuran or dimethylformamide by using lithium bistrimethylsilylamide or lithium diisopropylamide as a base.
- R 1 COX is generally synthesized by the use of a corresponding amine as a starting material according to methods as described in Tetrahedron Lett, 1994, 35, 839.
- R 1 is a C6-14 aryloxy group optionally substituted by one to three substituents selected from the substituent group ⁇
- R 1 COX is generally synthesized by the use of a corresponding phenol as a starting material according to methods as described in J of Med Chem (1983) 26, 264 and Synthesis (1993) 103.
- R 1 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group ⁇ , or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group ⁇
- R 1 COX is generally obtained in high yield by treating a corresponding carboxylic acid with thionyl chloride or oxalyl chloride according to methods as described in Jikken Kagaku Koza (Experimental Chemistry) , 4th Edition, Vol. 22, 115, Maruzen Co., Ltd. Oherwise, the compound (I) or a salt thereof is synthesized by the process 2 when R of the compound (I) is an optionally substituted Cl-6 alkyl group.
- R 2 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group ⁇ .
- the compound (III) or salt thereof is reacted with the compound (V) in a sealed tube in the presence of an acid such as hydrochloric acid or p-toluenesulfonic acid at a temperature of 0 to 100 0 C, preferably 90 to 100 0 C.
- This reaction proceeds also on microwave irradiation.
- the compound (V) may be generally synthesized in high yield by the use of a corresponding alcohol and ethyl orthoformate as starting materials according to methods as described in J. Am. Chem. Soc. 74, 554 (1952) and ibid. 77, 3801 (1955)
- such a compound (II) may be converted to a salt with, for example hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid or the like according to a conventional method.
- the compound (II) or the salt thereof is converted to an N-oxide enol compound (I):
- R is as defined above, and n is an integer of 1, by oxidation with an oxidizing agent such as hydrogen peroxide, a hydroperoxide or perbenzoic acid or the like at a temperature of -20°C to a room temperature in a solvent such as benzene, methanol, methylene chloride or chloroform for 1 hour to 3 days.
- an oxidizing agent such as hydrogen peroxide, a hydroperoxide or perbenzoic acid or the like at a temperature of -20°C to a room temperature in a solvent such as benzene, methanol, methylene chloride or chloroform for 1 hour to 3 days.
- the compound of the formula (I) or a pharmaceutically acceptable salt thereof is useful as a therapeutic agent for Alzheimer 'type dementia and may be orally or parenterally administered for treatment.
- the compound When used in the form of an oral preparation, the compound may be formulated into a solid preparation such as a powder, granules, capsules, tablets or the like or a liquid preparation such as a syrup, elixir or the like.
- a parenteral preparation When used in the form of a parenteral preparation, the compound may be formulated into an injection, an inhalation, a percutaneous preparation, a suppository or the like.
- the dose is varied depending on the kind of a disease to be treated, the age, sex, body weight and symptom of a patient, and administration route, the compound is administered in a dose of, in general, approximately 1 to 10 mg in terms of donepezil per day in one portion or several portions.
- the present invention is illustrated in detail with the following examples, which should not be construed as limiting the scope of the invention.
- the abbreviations used in the examples are common abbreviations generally known to those skilled in the art. Some of the abbreviations are described below.
- reaction mixture was allowed to cool to room temperature and was then concentrated under reduced pressure to remove the solvent.
- a saturated aqueous sodium hydrogencarbonate solution was added to the residue, followed by extraction with methylene chloride.
- the organic layer was dried (MgSO 4 ) and then concentrated under reduced pressure, and the resulting residue was purified by a silica gel column chromatography (n-hexane/ethyl acetate) to obtain the title compound (69.3 mg, yield: 27%).
- N, N-diisopropylcarbamoyl chloride (94.9 mg, 0.580 mmol) and 2 ml of pyridine were added to donepezil (200 mg, 0.527 mmol), and the reaction mixture was stirred in a sealed tube at 90°C for 5 days. The reaction mixture was allowed to cool to room temperature and was then concentrated under reduced pressure to remove the solvent. Ethyl acetate was added to the residue, followed by washing with a saturated aqueous sodium hydrogencarbonate solution and then a saturated aqueous sodium chloride solution.
- Donepezil (100 mg, 0.264 ⁇ unol) was dissolved in tetrahydrofuran (THF, 3 ml) under a nitrogen atmosphere and the resulting solution was cooled to - 60 0 C. Then, lithium bistrimethylsilylamide (1.0 M, a THF solution, 0.40 ml, 0.40 ⁇ unol) was poured into the reaction mixture. The resulting mixture was heated to -10 0 C from -6O 0 C over a period of 1.5 hours and then cooled to -60 0 C, and a THF solution (1 ml) containing phenyl chloroformate (0.050 ml, 0.40 mmol) was poured into the reaction mixture.
- THF tetrahydrofuran
- Example 1 In order to demonstrate the usefulness of the compound of the present invention as a drug, the following drug metabolism test was carried out by choosing the compound of Example 1 as a representative compound.
- the area under the blood concentration-time curve (AUC) for each of them is shown in Table 1 below.
- the compound of the formula (I) or a salt thereof, which is a prodrug of donepezil hydrochloride permits remission and reduction of effects of donepezil hydrochloride (e.g. vomit, diarrhea and nightmare) , and is therefore useful as a therapeutic agent for Alzheimer type dementia having smaller side effects.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A compound represented by the general formula: wherein R is an optionally substituted C1-6 alkyl group and the like, and n is an integer of 0 or 1, or a pharmaceutically acceptable salt thereof is expected to be effective in the remission and reduction of side effects (e.g. vomit, diarrhea and nightmare) observed in some cases after the administration of donepezil hydrochloride.
Description
'DESCRIPTION PRODRUG OF-DONEPEZIL HYDROCHLORIDE
Technical Field
The present invention relates to a novel prodrug of donepezil hydrochloride, which is a therapeutic agent for Alzheimer type dementia, a process for production thereof and a pharmaceutical composition containing them.
Background Art
In recent years,, senile dementia represented by Alzheimer type dementia has become a serious problem with a growth of the aged population, and the development of an excellent therapeutic agent for senile dementia is eagerly desired.
^ It has been reported that in case of Alzheimer type dementia, the amounts of neurotransmitters such as acetylcholine, norepinephrine and serotonin are decreased with the accumulation of β- amyloids. The cholinesterase inhibitor that controlled the decomposition of the acetylcholine was developed by focusing attention on the close relation to the decrease in the cognitive function including the memory to the degeneration of cholinergic neuron. The cholinesterase inhibitors used as a therapeutic agent for Alzheimer type dementia includes donepezil
hydrochloride, rivastigmine and galantamine, etc.
Among these acetylcholine inhibitors, donepezil hydrochloride is an excellent therapeutic agent characterized by a few peripheral side effect based on the high selectivity of acetylcholinesterase to butyrylcholinesterase and by the long half-life in blood etc. (see Japanese Patent No. 2578475, Japanese Patent No. 2777159 and J of Med Chem (1995) 38, 4821) . As a result of clinical tests, it has been confirmed that donepezil hydrochloride is effective against a mild or medium case of Alzheimer type dementia. The effect of donepezil hydrochloride is the suppression of the progress of dementia symptoms in a mild or medium case of Alzheimer type dementia. In addition, on the basis of the results of subsequent clinical tests, an additional application for launching donepezil hydrochloride with new efficacy and effect on a serious case of Alzheimer type dementia has been made.
Disclosure of Invention Donepezil hydrochloride is a very excellent therapeutic agent for Alzheimer type dementia from the viewpoint of efficacy, absorption, distribution, toxicity and the like and is most commonly used all over the world. Donepezil causes a rapid increase of its blood level after administration because of its satisfactory absorption and distribution, to exhibit its efficacy. On the other hand, it has been reported
that the side effects of donepezil hydrochloride, such as vomit, diarrhea and nightmare are observed which are considered to be due to the rapid increase of the blood level of donepezil caused soon after administration. The remission and reduction of the side effects (e.g. vomit, diarrhea and nightmare) caused in some cases are a problem to be solved for the present invention.
The present inventors earnestly made efforts in order to solve the above problem, and consequently could prevent the rapid increase of the blood level of donepezil by converting donepezil to a prodrug to retard the release of the pharmaceutical activity itself into blood. This prevention permits remission and reduction of the above-mentioned side effects (e.g. vomit, diarrhea and nightmare) observed in some cases, whereby the present invention has been accomplished.
That is, the present invention relates to a compound -represented by the formula (I):
(I) wherein R is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α, a carbamoyl group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxycarbonyl group optionally substituted by one to
three substituents selected from the substituent group α, a C2-6 alkanoyl group optionally substituted by one to three substituents selected from the substituent group α, or a C6-14 arylcarbonyl group optionally substituted by one to three substituents selected from the substituent group α; and n is an integer of 0 or 1, or a pharmaceutically acceptable salt thereof; said substituent group α consisting of a Cl-6 alkoxy group, a C2-6 alkenyl group, a Cl-6 alkyl group, a Cl-6 alkylthio group, a C2-6 alkynyl group, a C6-14 aryl group, a cyano group, a C3-8 cycloalkoxy group, a C3-8 cycloalkyl group, a C3-8 cycloalkylthio group, a halogen atom and a nitro group.
Further, the present invention also relates to a process for producing a compound represented by the formula (I ) :
(I) wherein R and n are as defined above, or a pharmaceutically acceptable salt thereof, which comprises the steps of; reacting a compound represented by the formula (III) :
(I I I)
or a salt thereof with a compound represented by the formula (IV) :
R1COX (IV)
wherein R1 is an amino group optionally substituted by one or two Cl-β alkyl groups, a C6-14 aryloxy group optionally substituted by, one to three substituents selected from the substituent group α as defined above, a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent α as defined above, or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group α as defined above; and X is a leaving group, or reacting a compound represented by the formula (III) :
(III)
or a salt thereof with a compound represented by the
formula (V) :
CH(OR2)3 (V)
wherein R2 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α as defined above, thereby obtaining a compound represented by the formula (II) :
(M)
wherein R is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α as defined above, a carbamoyl group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxycarbonyl group optionally substituted by one to three substituents selected from the substituent group α as defined above, a C2-6 alkanoyl group optionally substituted by one to three substituents selected from the substituent group α as defined above, or a C6-14 arylcarbonyl group optionally substituted by one to three substituents selected from the substituent group α as defined above, or a salt thereof, and if necessary, subjecting the compound of the formula (II) or a salt thereof to salt forming reaction
and/or oxidation reaction.
Still further, the present invention relates to a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as defined above, as an active ingredient.
The compound of the formula (I) of the present invention is expected to be effective in the treatment, prevention, remission, amelioration and the like of, for example, a cerebral accident (e.g. cerebral hemorrhage or cerebral infarction) , cerebral arteriosclerosis, or a head injury; and aprosexia,' lalopathy, hypobulia, emotional disturbance, memory- disturbance, hallucinatory-paranoid syndrome, behavioral abnormality which are associated with, for example, encephalitis or cerebral palsy.
In addition, the remission and reduction of, the side effects (e.g. vomit, diarrhea and nightmare) observed in some cases after the administration of donepezil hydrochloride are the expected advantages of the present invention.
Best Mode for Carrying Out the Invention
In the description in the present specification, the term "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom, an iodine atom or the like, preferably a chlorine atom or a bromine atom.
The term "C3-8 cycloalkyl group" means a
cyclic alkyl group of 3 to 8 carbon atoms. Preferable examples of this group are cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, etc. The term "Cl-6 alkyl group" means an alkyl group of 1 to 6 carbon atoms. Preferable examples ' of this "group are linear or branched alkyl groups such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, t-butyl group, n- pentyl group, isopentyl group, neopentyl group, n-hexyl group, 1-methylpropyl group, 1, 2-dimethylpropyl group, 1-ethylpropyl group, l-methyl-2-ethylpropyl group, 1- ethyl-2-methylpropyl group, 1, 1, 2-trimethylpropyl group, 1-methylbutyl group, 2-methylbutyl group, 1,1- dimethylbutyl group, 2, 2-dimethylbutyl group, 2- ethylbutyl group, 1, 3-dimethylbutyl group, 2- methylpentyl group, 3-methylpentyl group, etc. More preferable examples thereof are methyl group, ethyl group and n-propyl group. The term "C2-6 alkenyl group" means an alkenyl group of 2 to 6 carbon atoms. Preferable examples of this group are linear or branched alkenyl groups such as vinyl group, allyl group, 1-propenyl group, isopropenyl group, 1-buten-l-yl group, 1-buten- 2-yl group, l-buten-3-yl, 2-buten-l-yl group, 2-buten- 2-yl group, etc.
The term "C2-6 alkynyl group" means an alkynyl group of 2 to 6 carbon atoms. Preferable
examples of this group 'are linear or branched alkynyl groups such as ethynyl group, 1-propynyl group, 2- propynyl group, butynyl group, pentynyl group, hexynyl •group, etc. The term "Cl-6 alkoxy group" means a group formed by the replacement of a hydrogen atom of an ' alkyl group of 1 to 6 carbon atoms by an oxygen atom. This group includes, for example, methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, t-butoxy group, n-pentyloxy group, isopentyloxy group, sec-' pentyloxy group, t-pentyloxy group, n-hexyloxy group, isohexyloxy group, 1, 2-dimethylpropoxy group, 2- ethylpropoxy group, l-methyl-2-ethylpropoxy group, 1- ethyl-2-methylpropoxy group,, 1, 1, 2-trimethylpropoxy group, 1, 1-dimethylbutoxy group, 2, 2-dimethylbutoxy group, 2-ethylbutoxy group, 1, 3-dimethylbutoxy group, 2-methylpentyloxy group, 3-methylpentyloxy group and hexyloxy group. The term "C3-8 -cycloalkoxy group" means a group formed by the replacement of a hydrogen atom of a cyclic alkyl group of 3 to 8 carbon atoms by an oxygen atom. This group includes, for example, cyclopropoxy group, cyclobutoxy group, cyclopentyloxy group, cyclohexyloxy group, cycloheptyloxy group and cyclooctyloxy group.
The term "Cl-6 alkylthio group" means a group formed by the replacement of a hydrogen atom of an
alkyl group of 1 to 6 ea-rbon atoms by a sulfur atom. This group includes, for< -example, methylthio group, ethylthio group, n-propylthio group, isopropylthio group, n-butylthio group, • isobutyPthio group, t- butylthio group, n-pentylthio group, isopentylthio group, neopentylthio group, n-hexylthio group and 1- methylpropylthio group.
The term "C3-8 cycloalkylthio group" means a group formed by the replacement of a hydrogen atom of a cyclic alkyl group of 3 to 8 carbon atoms by a sulfur atom. This group includes, for example, cyclopropylthio group, cyclobutylthio group, cyclopentylthio group, cyclohexylthio group, cycloheptylthio group and cyclooctylthio group. The "C6-14 aryl group" includes, for example, phenyl group, naphthyl group and anthryl group. Of these, phenyl group is preferable.
The term "C6-14 aryloxycarbonyl group" means a group formed by bonding of a carbonyl group to the phenolic hydroxyl group of an aryloxy group of 6 to 14 carbon atoms. Preferable examples of this group are phenoxycarbonyl group, naphthyloxycarbonyl group, anthryloxycarbonyl group, etc. Phenoxycarbonyl group is more preferable. The term "C6-14 arylcarbonyl group" means a group formed by bonding of a carbonyl group to an aromatic ring of 6 to 14 carbon atoms. Preferable examples of this group are benzoyl group, naphthoyl
group, etc. Benzoyl group is more preferable.
The term "C2-6 alkanoyl group" means an alkanoyl group of 2 to 6 carbon atoms. Preferable examples of this group are acetyl group, propanoyl group, butanoyl group, pentanoyl group and hexanoyl group.
The term "substituent group α" means the group consisting of a Cl-6 alkoxy group, a C2-6 alkenyl group, a Cl-β alkyl group, a Cl-6 alkylthio group, a C2-6 alkynyl group, a C6-14 aryl group, a cyano group, a C3-8 cycloalkoxy group, a C3-8 cycloalkyl group, ; a C3-8 cycloalkylthio group, a halogen atom and a nitro group.
The term "pharmaceutically acceptable salt" means a salt of the compound (I) which can be used as an active agent of a pharmaceutical composition. Preferred examples of such a salt may include a mineral acid salt such as hydrochloride, hydrobromide, sulfate and nitrate; an inorganic acid salt such as perchlorate, phosphate, carbonate and bicarbonate; an organic carboxylate such as acetate, oxalate, maleate, tartarate, fumarate and citrate; an organic sulfonate such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate and camphorsulfonate; an amino acid salt such as aspartate and glutamate; a quaternary amine salt; an alkali metal salt such as sodium salt and potassium salt; and an alkali-earth metal salt such as magnesium salt and
calcium salt.
The term "salt'.' means the same meanings as those of the term "pharmaceutically acceptable salt" as mentioned above. Next, a process for producing the compound of the formula (I) of the present invention (hereinafter referred to as the compound (I); the same abbreviation applied to compounds represented by other formulas) or a salt thereof is explained below. The compound (I) or a salt thereof is synthesized by the use of a compound (III) or a salt thereof, which is donepezil or donepezil salt, as a starting material as shown below.
(in) o
R1^X υr CH(OR2)3
(IV) CV)
(H)
, [O]
That is, the synthesis is carried out by the following process 1 when R of the compound (I) is the carbamoyl group, the aryloxycarbonyl group, the alkanoyl group or the arylcarbonyl group.
Process 1
A compound (III)
(III) or a salt thereof is reacted with a compound represented by the formula (IV):
R1COX (IV)
wherein R1 is an amino group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxy group optionally substituted by one to three substituents selected from the substituent group α, a Cl-β alkyl group optionally substituted by one to three substituents selected from the substituent group α, or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group α; and X is a leaving group.
More specifically, when R1 is an amino group optionally substituted by one or two Cl-β alkyl groups, the reaction is carried out in pyridine solvent in a sealed tube at a temperature of 0 to 100°C, preferably 900C. When R1 is an Cβ-14 aryloxy group optionally substituted by one to three substituents selected from the substituent group α, or when R1 is an Cl-β alkyl group optionally substituted by a substituent (s)
selected from the substituent group α, or a C6-14 aryl group optionally substituted by a substituent (s) selected from the substituent gxoup α, the reaction is carried out at -60°C to room temperature in an inert solvent such as tetrahydrofuran or dimethylformamide by using lithium bistrimethylsilylamide or lithium diisopropylamide as a base.
As to the synthesis of the starting material (IV), when R1 is an amino group optionally substituted by one or two Cl-6 alkyl groups, R1COX is generally synthesized by the use of a corresponding amine as a starting material according to methods as described in Tetrahedron Lett, 1994, 35, 839. When R1 is a C6-14 aryloxy group optionally substituted by one to three substituents selected from the substituent group α, R1COX is generally synthesized by the use of a corresponding phenol as a starting material according to methods as described in J of Med Chem (1983) 26, 264 and Synthesis (1993) 103. When R1 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α, or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group α, R1COX is generally obtained in high yield by treating a corresponding carboxylic acid with thionyl chloride or oxalyl chloride according to methods as described in Jikken Kagaku Koza (Experimental Chemistry) , 4th Edition, Vol. 22, 115, Maruzen Co., Ltd.
Oherwise, the compound (I) or a salt thereof is synthesized by the process 2 when R of the compound (I) is an optionally substituted Cl-6 alkyl group.
Process 2
A compound (III)
(III) or a salt thereof is reacted with a compound represented by the formula (V) :
CH(OR2)3 (V)
wherein R2 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α.
More specifically, the compound (III) or salt thereof is reacted with the compound (V) in a sealed tube in the presence of an acid such as hydrochloric acid or p-toluenesulfonic acid at a temperature of 0 to 1000C, preferably 90 to 1000C. This reaction proceeds also on microwave irradiation. The compound (V) may be generally synthesized in high yield by the use of a corresponding alcohol and ethyl orthoformate as starting materials according to methods as described in J. Am. Chem. Soc. 74, 554
(1952) and ibid. 77, 3801 (1955)
Thus, according to the process 1 and the process 2, the compound (II)
(II) wherein R is as defined above, or a salt thereof is obtained.
If necessary, such a compound (II) may be converted to a salt with, for example hydrochloric acid, hydrobromic acid, p-toluenesulfonic acid or the like according to a conventional method. In addition, if necessary, the compound (II) or the salt thereof is converted to an N-oxide enol compound (I):
wherein R is as defined above, and n is an integer of 1, by oxidation with an oxidizing agent such as hydrogen peroxide, a hydroperoxide or perbenzoic acid or the like at a temperature of -20°C to a room temperature in a solvent such as benzene, methanol, methylene chloride or chloroform for 1 hour to 3 days. The compound of the formula (I) or a pharmaceutically acceptable salt thereof is useful as a
therapeutic agent for Alzheimer 'type dementia and may be orally or parenterally administered for treatment. When used in the form of an oral preparation, the compound may be formulated into a solid preparation such as a powder, granules, capsules, tablets or the like or a liquid preparation such as a syrup, elixir or the like. When used in the form of a parenteral preparation, the compound may be formulated into an injection, an inhalation, a percutaneous preparation, a suppository or the like. These preparations are produced according to conventional methods by adding pharmacologically and pharmaceutically acceptable preparation adjuvants to the active ingredient. Although the dose is varied depending on the kind of a disease to be treated, the age, sex, body weight and symptom of a patient, and administration route, the compound is administered in a dose of, in general, approximately 1 to 10 mg in terms of donepezil per day in one portion or several portions. The present invention is illustrated in detail with the following examples, which should not be construed as limiting the scope of the invention. The abbreviations used in the examples are common abbreviations generally known to those skilled in the art. Some of the abbreviations are described below.
A proton nuclear magnetic resonance spectrum was measured at 400 MHz by the use of CDCl3 as a solvent, and chemical shift is recorded in δ unit (ppm)
with respect to tetramethyl-sal-ra-ne and coupling constants were recorded 'in hertz- (Hz) . In a spectral pattern, s; singlet, d; :double£; t; triplet, and b; broad. Analytical thin-layer -chromatography (TLC) was carried out on a pre-coated silica gel plate (60F-254), followed by visualization and detection by the use of UV light and ethanolic phosphomolybdic acid. Example 1
Synthesis of l-benzyl-4- [ (1, 5, 6-trimethoxy-3H-inden) -2- yl] methylpiperidine
To donepezil (200 mg, 0.527 itttnol) were added 1 ml of trimethyl orthoformate and 2 ml of a 1.25 M solution of hydrogen chloride in methanol, and the reaction^ mixture was stirred in a sealed tube at 900C for 5 days. The reaction mixture was allowed to cool to room temperature and was then concentrated under reduced pressure to remove the solvent. Methylene chloride was added to the residue, followed by washing with a saturated aqueous sodium hydrogencarbonate solution. The organic layer was dried (MgSO4) and then concentrated under reduced pressure, and the resulting residue was purified by a silica gel column chromatography (NH-silica gel, n-hexane/ethyl acetate) to obtain the title compound (43.0 mg, yield: 21%).
In another process, donepezil (250 mg, 0.659 mmol), 1 ml of tπmethyl orthoformate and 3 ml of a 1.25 M solution of hydrogen chloride in methanol were placed in a sealed tube, and the reaction mixture was irradiated with a microwave at an output of 100 watts for 40 minutes at a reaction temperature of 90°C. The reaction mixture was allowed to cool to room temperature and was then concentrated under reduced pressure to remove the solvent. A saturated aqueous sodium hydrogencarbonate solution was added to the residue, followed by extraction with methylene chloride. The organic layer was dried (MgSO4) and then concentrated under reduced pressure, and the resulting residue was purified by a silica gel column chromatography (n-hexane/ethyl acetate) to obtain the title compound (69.3 mg, yield: 27%).
1H-NMR(CDCl3 ) 5:1.19-1.31 (2H,m) ,1.37-1.47 (IH, m) , 1.55- 1.62 (2H,m) , 1.85 (2H, dt, J=O .20, 1.16Hz) , 2.31 (2H, d, J= 0.72Hz) , 2.80(2H,b-d, J=I.16Hz) ,3.06(2H,s),3.41(2H,s), 3.80(3H,s),3.81(3H,s),3.84(3H,s),6.80(lH,s),6.88(lH, s, ) ,7.13-7.25(5H,m) . ESI-MS:m/z=394 (M+H+ ) .
Example 2
Synthesis of l-benzyl-4- [ ( 1-N, N- diisopropylcarbamoyloxy-5, 6-dimethoxy-3H-inden) -2- yl] methylpiperidine
N, N-diisopropylcarbamoyl chloride (94.9 mg, 0.580 mmol) and 2 ml of pyridine were added to donepezil (200 mg, 0.527 mmol), and the reaction mixture was stirred in a sealed tube at 90°C for 5 days. The reaction mixture was allowed to cool to room temperature and was then concentrated under reduced pressure to remove the solvent. Ethyl acetate was added to the residue, followed by washing with a saturated aqueous sodium hydrogencarbonate solution and then a saturated aqueous sodium chloride solution. The organic layer was dried (MgSO4) and then concentrated under reduced pressure, and the resulting residue was purified by a silica gel column chromatography (NH- silica gel, n-hexane/ethyl acetate) . Then, the mixture thus obtained was purified by a preparative thin-layer chromatography (methylene chloride/methanol) to obtain the title compound (47.0 mg, yield: 18%). 1H-NMR(CDCl3 ) 5:1.16-1.34 (14H,m) ,1.37-1.48 (lH,m) ,1.57- 1.64 (2H,m) ,1.84 (2H, dt, J=O .20, 1.16Hz) ,2.24 (2H, d, J=O .71Hz ) ,2.78 (2H,b-d, J=I.16Hz) ,3.16(2H,s),3.40(2H,s), 3.78 (3H,s) ,3.79 (3H, s) ,3.88-4.08 (2H,m) ,6.56 (IH, s) , 6.87 (IH, s) ,7.15-7.25 (5H,m) . ESI-MS:m/z=507 (M+H+ ) .
Example 3
Synthesis of l-benzyl-4- [ (l-phenoxycarbonyloxy-5, 6- dimethoxy-3H-inden) -2-yl] methylpiperidine
Donepezil (100 mg, 0.264 πunol) was dissolved in tetrahydrofuran (THF, 3 ml) under a nitrogen atmosphere and the resulting solution was cooled to - 600C. Then, lithium bistrimethylsilylamide (1.0 M, a THF solution, 0.40 ml, 0.40 πunol) was poured into the reaction mixture. The resulting mixture was heated to -100C from -6O0C over a period of 1.5 hours and then cooled to -600C, and a THF solution (1 ml) containing phenyl chloroformate (0.050 ml, 0.40 mmol) was poured into the reaction mixture. After slow heating to room temperature from -6O0C, the reaction mixture was stirred overnight and a saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was dried (MgSO4) and then concentrated under reduced pressure, and the resulting residue was purified by a preparative thin-layer chromatography (methylene chloride/methanol) to obtain the title compound (43.4 mg, yield: 33% ) .
1H-NMR(CDCl3) 5:1.24-1.38 (2H,m) , 1.43-1.54 (lH,m) ,
1.62 (2H,b-d, J=I.24Hz) , 1.89 (2H, b-t, J=I .07Hz) ,2.32 (2H,d,
J=O.71Hz) , 2.82 (2H,b-d,'j=1.07Hz) , 3.21 (2H, s) , 3.44 (2H, b- s) ,3.81 (3H, s) ,3.83 (3H, s) ,6.70 (IH, s) , 6.91 (IH, s) ,7.15- 7.25 (8H,m) ,7.32-7.37 (2H,m) . ESI-MS:m/z=500 (M+H+ ) .
Example 4
Synthesis of l-benzyl-4- [ ( l-benzoyloxy-5, 6-dimethoxy- 3H- inden) -2-yl]methylpiperidine
The title compound (40.3 mg, yield: 32%) was obtained according to the process described in Example 3, except for reacting benzoyl chloride (0.046 mL) in place of phenyl chloroformate with donepezil (100 mg,' 0.264 mmol) .
1H-NMR(CDCl3 ) 6:1.20-1.32 (3H,m) , 1.35-1.43 (lH,m) , 1.47- 1.55 ( IH, m) 1.71-1.83 (2H,m) 2.06-2.12 (2H,m) ,2.66- 2.76(2H,m) , 2.99 (IH, d, J=I .72Hz) , 3.38 (2H, s) , 3.62 (lH,d, J=I .72Hz) , 3.86 (3H, s) ,3.92 (3H, s) ,6.84 (IH, s) ,7.14 (IH, s) ,7.15 -7.27 (7H,m) ,7.38 ( IH, t, J=O .75Hz) ,7.62 (2H, d, J=O .75Hz) . ESI-MS:m/z=484 (M+H+ ) .
The title compound (50.2 mg, yield: 23%) was obtained according to the process described in Example 1, except for reacting triethyl orthoformate (1 πiL) in place of trimethyl orthoformate with donepezil (200 mg, 0.528 mmol) .
1H-NMR(CDCl3 )δ:l.23-1.35 (2H,m), 1.30 (3H, t, J=O .70Hz) ,1.38- 1.48 (IH, m) , 1.56-1.63 (2H,m) , 1.89 (2H, b-t , J=I .10Hz) , 2.30 (2H,d, J=O.71Hz) , 2.83 (2H, b-d, J=I .10Hz) ,3.08 (2H, s),3.47(2H,s),3.80(3H,s),3.83(3H,s),4.00 (2H, q, J=O .70Hz) , 6.77 (IH, s) ,6.88 (IH, s) ,7.15-7.27 (5H,m) . ESI-MS:m/z=408 (M+H+ ) .
Example 6
Synthesis of l-benzyl-4- [ (l-acetoxy-5, 6-dimethoxy-3H- inden) - 2-yl] methylpiperidine
The title compound (71.2 mg, yield: 43%) was obtained according to the process described in Example 3, except for reacting acetyl chloride (0.042 mL) in place of phenyl chloroformate with donepezil (150 mg, 0.396 mmol) . 1H-NMR(CDCl3 ) δ: 1.20-1.34 ( 3H, m) , 1.44-1.52 (2H,m) , 1.72-
1.86(3H,m) ,2.18-2.23 ( IH, m) , 2.20 (3H, s ) , 2.69-2.76 (2H,m) , 2.74 (IH, d, J=I.70Hz) ,3.67 (2H, s) ,3.78 (IH, d, J=I.70Hz) ,3.81 (3H, s) ,3.90 (3H,s) ,6.81 (IH, s) ,7.03 (IH, s) , 7.13-7.25(5H,m) . ESI-MS :m/z=423 (M+H+ ).
Example 7
Synthesis of l -benzyl-4 - [ ( 1 , 5 , 6-trimethoxy- 3H-inden) -2 - yl ] methylpiperidine- l -oxide
To l-benzyl-4- [(1,5, 6-trimethoxy-3H-inden) -2- yl]methylpiperidine (21.0 mg, 0.053 mmol) were added 2 mL of methanol and 0.5 mL of a 30% aqueous hydrogen peroxide solution, and the reaction mixture was stirred at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure to remove the solvent, and a saturated aqueous sodium hydrogencarbonate solution was added to the residue, followed by extraction with methylene chloride. The organic layer was dried (MgSO4) and then concentrated under reduced pressure, and the resulting residue was purified by a thin-layer chromatography to obtain the title compound (6.9 mg, yield: 32%).
1H-NMR(CDCl3 )δ: 1.40-1.52 ( IH, m) , 1.53 (2H, b-d, J=I .44Hz) , 2.09-2.35(3H,m) ,2.38 (2H, d, J=O .86Hz) , 2.96-3.16 (3H,m) ,
3.04 (2H,s) ,3.79 (3H,s) ,3.80 (3H,s) ,3.83 (3H,s) ,4.34 (2H,s) , 6.80 (IH, s) , 6.86 (IH, s) , 7.30-7.45 (5H, m) . ESI-MS:m/z=410 (M+H+ ) .
Example 8 Synthesis of 2- [ ( l-benzylpiperidine-l-oxid-4- yl) methyl] -5, 6-dimethoxy-3H-inden-l-yl benzoate
The title compound (14.4 mg, yield: 29%) was obtained by the same process as in Example 7 except for reacting l-benzyl-4- [ ( l-benzoyloxy-5, 6-dimethoxy-3H- inden)- 2-yl]methylpiperidine (47.3 mg, 0.098 mmol) with 0.5 mL of a 30% aqueous hydrogen peroxide solution.
1H-NMR(CDCl3)O: 1.33 ( IH, b-d, J=I .38Hz) , 1.43-1.53 ( IH, m), 1.43-1.53 ( IH, m) ,1.63 (IH, b-d, J=I .38Hz) , 1.83 (IH, dd, J= 0.55, 1.44Hz), 2.04 ( IH, dq, J=O .38, 1.3Hz) , 2.15 (IH, dq, J=
0.38,1.3Hz) , 2.25(lH,dd, J=O.55, 1.44Hz) , 2.88-3.10 (5H,m) , 3.59 (IH, d, J=I.73Hz) ,3.87 (3H,s) ,3.93(3H,s) ,4.29(2H,s) , 6.83 (IH, s) ,7.14 (IH, s) ,7.21-7.27 (2H,m) ,7.28-7.35 (3H,m) , 7.36-7.42 (3H7ItI) ,7.53-7.58 (2H,m) . ESI-MS:m/z=500 (M+H+) . Test Example 1 Evaluation of metabolism
In order to demonstrate the usefulness of the
compound of the present invention as a drug, the following drug metabolism test was carried out by choosing the compound of Example 1 as a representative compound. The compound of Example 1 was administered to fasted male rats (aged 8 weeks, n= 2) in the form of a solution of the compound in 10% DMSO/10% Tween 20, and the blood levels of the original compound and donepezil produced in the living body were periodically measured. The area under the blood concentration-time curve (AUC) for each of them is shown in Table 1 below.
Table 1
The results of Table 1 indicate that the compound of Example 1 can prevent the rapid increase of the blood level more effectively than donepezil hydrochloride, thereby retarding the release of the pharmaceutical activity itself into blood.
This prevention permits remission and reduction of the above-mentioned side effects (e.g. vomit, diarrhea and nightmare) observed in some cases, whereby the present invention has been accomplished.
Industrial Applicability
According to the present invention, the compound of the formula (I) or a salt thereof, which is a prodrug of donepezil hydrochloride, permits remission and reduction of effects of donepezil hydrochloride (e.g. vomit, diarrhea and nightmare) , and is therefore useful as a therapeutic agent for Alzheimer type dementia having smaller side effects.
Claims
1. A compound represented by the formula (i;
(I) wherein R is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α, a carbamoyl group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxycarbonyl group optionally substituted by one to three substituents selected from the substituent group α, a C2-6 alkanoyl group optionally substituted by one to three substxtuents selected from the substituent group α, or a C6-14 arylcarbonyl group optionally substituted by one to three substituents selected from the substituent group α; and n is an integer of 0 or 1, or a pharmaceutically acceptable salt thereof; said substituent group α consisting of a Cl-6 alkoxy group, a C2-6 alkenyl group, a Cl-6 alkyl group, a Cl-6 alkylthio group, a C2-6 alkynyl group, a C6-14 aryl group, a cyano group, a C3-8 cycloalkoxy group, a C3-8 cycloalkyl group, a C3-8 cycloalkylthio group, a halogen atom and a nitro group.
(I)- wherein R and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof, which comprises the steps of; reacting a compound represented by the formula (III) :
(Ml)
or a salt thereof with a compound represented by the ' formula (IV) :
R1COX (IV)
wherein R1 is an amino group optionally substituted by one or two Cl-6 alkyl groups, a C6-14 aryloxy group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1, a Cl-β alkyl group optionally substituted by one to three substituents selected from the substituent α as defined in claim 1, or a C6-14 aryl group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1; and X is a leaving group, or reacting a compound represented by the formula (III) :
(III)
or a salt thereof with a compound represented by the formula (V) :
wherein R2 is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1, thereby obtaining a compound represented by the formula (II) :
(M)
wherein R is a Cl-6 alkyl group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1, a carbamoyl group optionally substituted by one or two Cl-β alkyl groups, a C6-14 aryloxycarbonyl group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1, a C2-6 alkanoyl group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1, or a C6-14 arylcarbonyl group optionally substituted by one to three substituents selected from the substituent group α as defined in claim 1, or a salt thereof, and if necessary, subjecting the compound of the formula (II) or a salt thereof to salt forming reaction and/or oxidation reaction.
3. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof according to claim 1, as an active ingredient. -
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005319382A JP2008280248A (en) | 2005-11-02 | 2005-11-02 | Prodrug of donepezil hydrochloride which is therapeutic agent for alzheimer type dementia |
JP2005-319382 | 2005-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007052541A1 true WO2007052541A1 (en) | 2007-05-10 |
Family
ID=37636051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/321443 WO2007052541A1 (en) | 2005-11-02 | 2006-10-20 | Prodrug of donepezil hydrochloride |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2008280248A (en) |
WO (1) | WO2007052541A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247563B2 (en) | 2006-12-11 | 2012-08-21 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
WO2016091079A1 (en) * | 2014-12-11 | 2016-06-16 | 诺瑞特国际药业股份有限公司 | Donepezil derivatives and uses thereof |
CN110548005A (en) * | 2018-05-30 | 2019-12-10 | 南京诺瑞特医药科技有限公司 | Sustained-release injection preparation containing donepezil derivative |
CN116018140A (en) * | 2020-08-14 | 2023-04-25 | 株式会社钟根堂 | Donepezil Ji Mi palmitate or pharmaceutically acceptable salts thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101980534B1 (en) * | 2019-04-05 | 2019-05-21 | 주식회사 종근당 | Donepezil myristyloxymethyl ether or its pharmaceutically acceptable salt |
KR20220059300A (en) * | 2020-11-02 | 2022-05-10 | 주식회사 종근당 | Acid addition salts of indene derivative prodrug and its preparation methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296560A2 (en) * | 1987-06-22 | 1988-12-28 | Eisai Co., Ltd. | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease |
EP0365194A2 (en) * | 1988-10-18 | 1990-04-25 | Pfizer Inc. | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides |
WO2002006236A1 (en) * | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
-
2005
- 2005-11-02 JP JP2005319382A patent/JP2008280248A/en active Pending
-
2006
- 2006-10-20 WO PCT/JP2006/321443 patent/WO2007052541A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0296560A2 (en) * | 1987-06-22 | 1988-12-28 | Eisai Co., Ltd. | 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease |
EP0365194A2 (en) * | 1988-10-18 | 1990-04-25 | Pfizer Inc. | Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides |
WO2002006236A1 (en) * | 2000-07-14 | 2002-01-24 | F. Hoffmann-La Roche Ag | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
Non-Patent Citations (3)
Title |
---|
BURKHART J P ET AL: "Preparation of alpha-keto ester enol acetates as potential prodrugs of human neutrophil elastase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 1-6, 6 January 1998 (1998-01-06), pages 63 - 64, XP004136623, ISSN: 0960-894X * |
PATEL J P ET AL: "Enol Esters as Potential Prodrugs I. Stability and Enzyme-Mediated Hydrolysis of alpha-Acetoxystyrene", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 5, 1980, pages 329 - 333, XP002415940 * |
SINGH G ET AL: "PRODRUG APPROACH IN NEW DRUG DESIGN AND DEVELOPMENT", JOURNAL OF SCIENTIFIC & INDUSTRIAL RESEARCH, vol. 55, July 1996 (1996-07-01), pages 497 - 510, XP001029288 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8247563B2 (en) | 2006-12-11 | 2012-08-21 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
US8580822B2 (en) | 2006-12-11 | 2013-11-12 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
WO2016091079A1 (en) * | 2014-12-11 | 2016-06-16 | 诺瑞特国际药业股份有限公司 | Donepezil derivatives and uses thereof |
CN105732478A (en) * | 2014-12-11 | 2016-07-06 | 南京诺瑞特医药科技有限公司 | Donepezil derivative and application thereof |
TWI607993B (en) * | 2014-12-11 | 2017-12-11 | 諾瑞特國際藥業股份有限公司 | Donepezil derivatives and their use |
US20180250278A1 (en) * | 2014-12-11 | 2018-09-06 | Noratech Pharmaceuticals, Inc. | Donepezil derivative and use thereof |
US10080746B2 (en) | 2014-12-11 | 2018-09-25 | Noratech Pharmaceuticals, Inc. | Donepezil derivative and use thereof |
CN105732478B (en) * | 2014-12-11 | 2020-04-24 | 南京诺瑞特医药科技有限公司 | Donepezil derivative and use thereof |
US10632111B2 (en) | 2014-12-11 | 2020-04-28 | Nanjing Noratech Pharmaceuticals Co., Ltd. | Donepezil derivative and use thereof |
CN110548005A (en) * | 2018-05-30 | 2019-12-10 | 南京诺瑞特医药科技有限公司 | Sustained-release injection preparation containing donepezil derivative |
CN110548005B (en) * | 2018-05-30 | 2021-08-31 | 南京诺瑞特医药科技有限公司 | Sustained-release injection preparation containing donepezil derivative |
CN116018140A (en) * | 2020-08-14 | 2023-04-25 | 株式会社钟根堂 | Donepezil Ji Mi palmitate or pharmaceutically acceptable salts thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2008280248A (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007052541A1 (en) | Prodrug of donepezil hydrochloride | |
US10590142B2 (en) | Deuterated amlexanox | |
RU2241001C2 (en) | Derivatives of galanthamine, method for their preparing, medicinal agent based on thereof and method for its preparing | |
ES2336572T3 (en) | 1-BENCIL-4- OXALATE (5,6-DIMETOXI-1-INDANONA) -2-IL-METHYL-PIPERIDINE (DONEPEZYL OXALATE) AND ITS POLYMORPHES. | |
WO2000051985A1 (en) | Fluorides of 4-substituted piperidine derivatives | |
EP2871184B1 (en) | Benzodioxole derivative and preparation method and use thereof | |
JP2680456B2 (en) | Stereospecific method for producing enantiomers of furo [3,4-C] pyridine | |
EP1209151B1 (en) | 4-substituted piperidine derivatives | |
ES2206449T3 (en) | INHIBITORS OF CHOLINESTERASES, PHARMACEUTICAL COMPOSITIONS AND THEIR USES. | |
US6277866B1 (en) | 1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine | |
FI98459C (en) | Process for the preparation of therapeutically useful 5-ethano-2,3,4,5-1H-2-benzazepin-7-ol carbamate derivatives | |
JP2000319257A (en) | 1-benzyl-4-[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl methyl piperidine | |
JP4242048B2 (en) | 4-substituted piperidine derivatives | |
EP3768679B1 (en) | Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same | |
JP2006248938A (en) | Boron-containing quinazoline derivative | |
Santos et al. | Studies towards the construction of alkylidene quinolizidines: the total synthesis of homopumiliotoxin 223G | |
KR100659679B1 (en) | 1-benzyl-4-[5,6-dimethoxy-2-fluoro-1-indanon-2-yl]methylpiperidine | |
JP4242032B2 (en) | 4-Substituted piperidine derivative fluoride | |
US6906083B2 (en) | 4-substituted piperidine compound | |
Ochiai et al. | Orally active PDE4 inhibitor with therapeutic potential | |
ES2214506T3 (en) | INTERMEDIATE PROCEDURES AND COMPOUNDS FOR THE PREPARATION OF 5,7-DIHIDRO-3- (2- (1-BENCILPIPERIDIN-4-IL) ETIL) -6H-PIRROLO- (4,5-F) -1,2-BENCISOXAZOL-6 -ONA. | |
Calder | The development of one-pot multi-reaction processes for the synthesis of natural products and biologically active compounds | |
Mancinelli | Exploring Novel Modes of Activation via Main-Group Elements | |
EP2576553A2 (en) | Highly selective asymmetric hydroformylation of (1s,4r) or (1r,4s)-2-azabicyclo[2.2.1]hept-5-en-3- one (+) or (-)-lactam | |
Mitchell | The Directed Dihydroxylation of Homoallylic Trichloroacetamides and Trifluoroacetamides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06822412 Country of ref document: EP Kind code of ref document: A1 |